Medinet Co

Medinet Co EV/EBIT

The EV/EBIT (Enterprise Value to EBIT) of Medinet Co (2370.T) as of Oct 27, 2026 is -5.70. In the previous year, EV/EBIT (Enterprise Value to EBIT) was -6.11 — a change of -6.77% (higher).

EV/EBIT

-5.70

YoY

-6.77%

Last updated:

EV/EBIT (Enterprise Value to EBIT) of Medinet Co is 2025 -5.70 . EV/EBIT (Enterprise Value to EBIT) of Medinet Co was 2024 -6.11 . It decreases by -6.77% higher compared to the previous year.

The Medinet Co EV/EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/EBIT
Date
EV/EBIT
Jan 1, 2018
-2.72 JPY
Jan 1, 2019
-8.17 JPY
Jan 1, 2020
-8.89 JPY
Jan 1, 2021
-9.88 JPY
Jan 1, 2022
-6.18 JPY
Jan 1, 2023
-5.78 JPY
Jan 1, 2024
-6.11 JPY
Jan 1, 2025
-5.70 JPY
The Medinet Co EV/EBIT history
YEAREV/EBITYoY
-5.70-6.77%
-6.11+5.81%
-5.78-6.51%
-6.18-37.48%
-9.88+11.13%
-8.89+8.87%
-8.17+200.76%
-2.72-40.59%
-4.57-6.69%
-4.90+3.61%
-4.73-19.22%
-5.85-86.26%
-42.61+156.69%
-16.60-33.23%
-24.86-155.76%
44.58+27.34%
35.01-502.41%
-8.70-77.34%
-38.40+6.49%
-36.06—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Medinet Co Valuation

Details

Historical Valuation Multiples

ⓘ

Price-to-Earnings Ratio (P/E)

The P/E ratio divides Medinet Co's share price by its earnings per share. It tells you how many years of current earnings you are "paying for" when you buy the stock. A P/E of 20 means you pay $20 for every $1 of annual earnings. The S&P 500 historically trades at an average P/E of roughly 15–17. A P/E significantly above that may signal high growth expectations; one below may indicate undervaluation — or declining business quality.

Price-to-Sales Ratio (P/S)

The P/S ratio divides market capitalization by total revenue. Unlike the P/E ratio, it works even for companies that are not yet profitable, making it essential for evaluating high-growth firms. A P/S below 1.0 may indicate undervaluation, while ratios above 10 are typically reserved for fast-growing tech or SaaS companies with high expected future margins.

Price-to-EBIT Ratio

This ratio relates Medinet Co's market price to its operating earnings, excluding the effects of debt structure and tax jurisdiction. It is particularly useful for comparing companies across different countries or with different levels of leverage, because it focuses purely on operational profitability. Lower values suggest cheaper operational earnings.

How to Use This Chart

This chart plots Medinet Co's valuation multiples over time. Compare the current P/E, P/S, and P/EBIT to their own historical averages — if the current ratio is well below the multi-year average, the stock may be relatively cheap compared to its own track record. Combine this with industry comparisons: a P/E that looks high in absolute terms may be justified if Medinet Co grows earnings faster than its peers.

Medinet Co Stock analysis

What does Medinet Co do? MEDINET Co., Ltd. generates revenue through its Cell Processing Industry segment, which offers comprehensive support services for immune cell therapy, including clinical use from companies, universities, and research institutes, outsourcing cell processing for clinical trials, and operating cell culture processing facilities. The Cellular Medical Products segment focuses on research and development to obtain approval for manufacturing and marketing cellular medical products. The company serves clients in the healthcare sector, particularly entities involved in immune cell therapy and cellular medical product development. The Cell Processing Industry segment provides outsourcing services for cell processing in clinical trials, catering to companies, universities, and research institutes seeking specialized processing capabilities. The Cellular Medical Products segment develops cellular medical products requiring regulatory approval, targeting manufacturers and marketers in the medical field. Both segments operate under MEDINET's expertise in cell processing and medical product development. MEDINET's business model relies on delivering specialized cell processing services and supporting the regulatory approval process for cellular medical products. The company's clients include organizations engaged in immune cell therapy research and development, as well as those seeking to commercialize cellular medical products. The dual-segment approach ensures comprehensive coverage of the cell processing and medical product development lifecycle. Medinet Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Medinet Co stock

EV/EBIT (Enterprise Value to EBIT) of Medinet Co is -5.70 in 2025.

EV/EBIT (Enterprise Value to EBIT) of Medinet Co changed from -6.11 to -5.70, representing a -6.77% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EV/EBIT (Enterprise Value to EBIT) Medinet Co since 2006 – with annual values, charts, and detailed analysis.

The EV/EBIT ratio measures a company's enterprise value relative to its operating earnings. It accounts for debt, making it useful for comparing companies with different capital structures.

EV/EBIT = Enterprise Value / Earnings Before Interest and Taxes

To evaluate EV/EBIT (Enterprise Value to EBIT)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/EBIT (Enterprise Value to EBIT).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/EBIT (Enterprise Value to EBIT)'s Medinet Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Medinet Co

All Key Metrics — Medinet Co